XBKK
MEGA
Market cap771mUSD
Nov 12, Last price
29.75THB
Name
Mega Lifesciences PCL
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in Bangkok, Thailand, in 1982, Mega Lifesciences Public Company Limited, a subsidiary of Unistretch Limited, operates as a comprehensive pharmaceutical and wellness enterprise. Its primary activities encompass the development, promotion, and distribution of a broad spectrum of health-related products, including nutritional supplements, prescription medicines, over-the-counter (OTC) remedies, botanical solutions, vitamins, and everyday consumer goods. The company structures its operations across three main divisions: Brands, Distribution, and Original Equipment Manufacture. Mega Lifesciences offers an extensive array of complementary medicines targeting various health concerns such as bone and joint health, pediatric care, diabetes management, cardiovascular support, digestive and liver wellness, skin health, weight management, overall well-being, men's and women's specific needs, and sports nutrition. Its OTC portfolio addresses common issues like gastrointestinal discomfort and pain. Furthermore, the prescription drug division covers crucial therapeutic areas including iron deficiency, anticoagulation, diabetology, cardiology, dermatology, gastroenterology, neurology, pain relief, osteoporosis, respiratory conditions, urology, oncology, and nephrology. Beyond its proprietary product lines, the company also provides third-party logistical and marketing services. Additionally, Mega Lifesciences is involved in managing wellness centers and offers specialized services in software design, development, and related technological solutions. The company maintains a significant global footprint, with operations spanning the Asia Pacific region, the Middle East, Africa, and the Commonwealth of Independent States.
Key people
Vivek Dhawan
Chief Executive Officer, Executive Director, Chief Coach · since 2013
Thomas Abraham
Chief Financial Officer, Executive Director, Head Coach · since 2013
Paramjit Sawhney
President - International, Head Coach · since 2000
Duangnapha Tongsiri
President - Thailand Mega We Care, Head Coach · since 1996
Girish Wadhwa
President - Myanmar, Head Coach · since 1998
Manoj Gurbuxani
Deputy Chief Financial Officer · since 2020
Sujintana Boonworapat
Company Secretary · since 2000
Non-Executive Director · since 2022
Sameera Shah
Non-Executive Director · since 2022
Non-Executive Director · since 2022
Non-Executive Director · since 2022
Yim Kam Chi
Independent Vice Chairman of the Board · since 2022
Vijay Karwal
Independent Director · since 2021
Thor Santhisiri
Independent Director · since 2013
Nithinart Sinthudeacha
Independent Director · since 2023
Mechai Viravaidya
Independent Chairman of the Board · since 2013
Valuation
Title THB in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||